+1 858-523-8231
Login | Register
AA Blocks, Building Blocks, Catalysts, Inhibitors
Login | Register
Home Other Building Blocks 1362850-20-1
1362850-20-1,MFCD28963973
Catalog No.:AA01EO7R

1362850-20-1 | Seletalisib

Pack Size
Purity
Availability
Price(USD)
Quantity
  
1mg
95%
1 week  
$134.00   $94.00
- +
10mg
98+%
1 week  
$189.00   $133.00
- +
25mg
98+%
1 week  
$319.00   $224.00
- +
50mg
98+%
1 week  
$492.00   $344.00
- +
100mg
98+%
1 week  
$816.00   $571.00
- +
  • Technical Information
  • Properties
  • Downstream Synthesis Route
  • Literature
  • Request for Quotation
  • Download SDS
  • Technical Information
  • Properties
  • Downstream Synthesis Route
  • Literature
Technical Information
Catalog Number:
AA01EO7R
Chemical Name:
Seletalisib
CAS Number:
1362850-20-1
Molecular Formula:
C23H14ClF3N6O
Molecular Weight:
482.8451
MDL Number:
MFCD28963973
SMILES:
[O-][n+]1cccc(c1)c1nc2c(cc1[C@H](C(F)(F)F)Nc1ncnc3c1nccc3)cccc2Cl
Properties
Computed Properties
 
Complexity:
690  
Covalently-Bonded Unit Count:
1  
Defined Atom Stereocenter Count:
1  
Heavy Atom Count:
34  
Hydrogen Bond Acceptor Count:
9  
Hydrogen Bond Donor Count:
1  
Rotatable Bond Count:
4  
XLogP3:
4  

Downstream Synthesis Route

[1]CurrentPatentAssignee:UCB-WO2012/32334,2012,A1

[2]CurrentPatentAssignee:UCB-WO2012/32334,2012,A1

[1]CurrentPatentAssignee:UCB-WO2012/32334,2012,A1

[2]CurrentPatentAssignee:UCB-WO2018/219772,2018,A1

[1]CurrentPatentAssignee:UCB-WO2012/32334,2012,A1

[2]CurrentPatentAssignee:UCB-WO2012/32334,2012,A1

[1]CurrentPatentAssignee:UCB-WO2012/32334,2012,A1

[2]CurrentPatentAssignee:UCB-WO2012/32334,2012,A1

[3]CurrentPatentAssignee:UCB-WO2018/219772,2018,A1

[1]CurrentPatentAssignee:UCB-WO2012/32334,2012,A1

[2]CurrentPatentAssignee:UCB-WO2012/32334,2012,A1

Literature

Title: Seletalisib: Characterization of a Novel, Potent, and Selective Inhibitor of PI3Kδ.

Journal: The Journal of pharmacology and experimental therapeutics 20170601

Title: First-in-human studies of seletalisib, an orally bioavailable small-molecule PI3Kδ inhibitor for the treatment of immune and inflammatory diseases.

Journal: European journal of clinical pharmacology 20170101

Title: Allen RA, et al. Seletalisib: Characterization of a Novel, Potent, and Selective Inhibitor of PI3Kδ. J Pharmacol Exp Ther. 2017 Apr 25. pii: jpet.116.237347.

Quotation Request
Company Name:
*
Contact Person:
*
Email:
*
Quantity Required:
*
Country:
Additional Info:
SDS
Related Products of 1362850-20-1
1362850-20-1

1362850-20-1
Building Blocks
More >
Tags:1362850-20-1 Molecular Formula|1362850-20-1 MDL|1362850-20-1 SMILES|1362850-20-1 Seletalisib